dkNET community events and announcements in September, 2022

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.

dkNET News

• D-Challenge: The D-Challenge is a collaborative bioinformatics challenge hosted by  dkNET & the(sugar)science. Participants utilize online digital resources to generate hypotheses surrounding Type 1 Diabetes. Registration deadline is extended to October 1, 2022! Win awards totaling $50K! Learn more: https://dknet.org/about/blog/2425

• Resources for Research Data Management: Are you ready for the new NIH Data Management and Sharing mandates starting on January 25, 2023? dkNET has resources to help you find data repositories and prepare your data management and sharing plan (DMSP). Check out these resources:  

• Research Data Management Overview

• Suggested data repositories (recommended by NIDDK domain experts, Nature Scientific Data, PLOS One, NLM NIH Data Sharing Repositories, Science).

• NIH Data Sharing Website

• Presentation on implementation of the NIH DMS Policy

• Webinar Slides: A Conversation with NIH: Implementing the New Data Management and Sharing Policy. Part 1: Understanding the New NIH Data Management and Sharing Policy

• New Publication: dkNET PI Dr. Maryann Martone and Dr. Richard Nakamura edited a special collection of 10 articles on the new NIH Data Sharing Policy in Harvard Data Science Review. Check out the introduction and these articles at: https://hdsr.mitpress.mit.edu/pub/yb0lddel/release/1

• Meet dkNET team at HIRN 2022 Annual Investigator Meeting: Drs. Jeffrey Grethe and Ko-Wei Lin are attending the HIRN (Human Islet Research Network) 2022 Annual Investigator Meeting. If you plan to attend this meeting, stop by our poster or schedule a meeting with us to learn more about dkNET.org and how we can help with your research!

• New Resources added to dkNET
• Secrepedia (RRID:SCR_022590) is an encyclopedia of white and brown adipocyte secretome in mouse models and humans as a key prerequisite to elucidating the role of these mediators in normal physiology and disease.

• VDJbase (RRID:SCR_022599) is an open source adaptive immune receptor genotype and haplotype database. Core collection is inferred from immune receptor repertoire sequences and genomically derived material. It provides customisable reports, which allow users to study gene and allele usage in various ways.

• AIRR Data Commons (RRID:SCR_022597) is a network of distributed repositories that adhere to standards set out by the AIRR Community. This collection contains standards and repositories either created by the AIRR community or approved for use within the AIRR community.

• AIRR Community (RRID:SCR_022598) is a research driven group that is organizing and coordinating stakeholders in use of next generation sequencing technologies to study antibody/B-cell and T-cell receptor repertoires. It develops and promotes standards and recommendations for obtaining, analyzing, curating and comparing/sharing AIRR-seq datasets;using and validating tools for analyzing AIRR-seq data;relating AIRR-seq datasets to other “big data” sets, such as microarray, flow cytometric, and MiSeq and single-cell gene-expression data; legal and ethical issues involving use and sharing of AIRR-seq data sets derived from human sources.

Events in September 2022

Sep. 01, 2022

D-Challenge Registration Deadline (Extended to October 1, 2022)

The D-Challenge is a community research challenge designed to increase awareness and use of the rich ecosystem of on-line tools and data findable through dkNET to develop a compelling hypothesis about the biology, treatment, or sequelae of Type 1 Diabetes.  It is open to participants of all skill levels, from students to skilled bioinformaticians and data scientists.

The goal in this challenge is to bring investigators across disciplines to apply their skills and passion to the problem of T1D:  its biology, treatment and sequelae, through the use of a rich interconnected ecosystem of data tools and resources.  The extensive resources and tools hosted through dkNET provide the opportunity to catalyze searches for novel pathways implicated in disease pathophysiology and / or identify new therapeutic targets.  As a partner in the D-Challenge, dkNET provides access to these resources and tools in an easily available setting, fostering discovery by the broad community of investigators focused on T1D.

More Information: https://dknet.org/about/blog/2425

Sep. 06, 2022 

HIRN Webinar: Reprogramming Human Regulatory T Cells to Quell Autoimmunity and Transplant Rejection

Topics to be Discussed:

- What is a regulatory T cell (Treg)? When were they first discovered? What is a chimeric antigen receptor (CAR)?

- How heterogenous is the Treg compartment? Do different Treg subsets perform different functions? How do tissue-resident Tregs differ from those in the periphery?

- What are the hurdles in utilizing Tregs? Does engineering Tregs create new opportunities or new challenges?

- How far along are Tregs in the clinic?

Presentation by: Leonardo Ferreira, PhD, Medical University of South Carolina & Everett Meyer, MD, PhD, Stanford University

Webinar Date: September 6, 2022 at 10:00-11:00AM PT

More Information: https://cityofhope.zoom.us/meeting/register/tJUpcOuorTMjG9MamR5M_qO1kwHAXh-wJQp1

Sep. 08, 2022 

Bay Area Metabolism Meeting 2022

BAMM started in 2019 and is a one-day symposium hosted by Stanford University and Stanford Diabetes Research Center with an amazing collection of speakers from Stanford, UC Berkeley, and UCSF. The goal is to learn more about the latest science to promote new ideas, projects, and collaborations.

Location:  Stanford, CA, USA

More Information: https://www.bayareametabolismmeeting.com/ 

Sep. 09, 2022

NIDDK Obesity Research Task Force Symposium

The epidemic of obesity in adults and children is not limited to the United States. Obesity prevalence is increasing globally and can co-exist with malnutrition and stunting. While treating people with obesity-related comorbidities can overwhelm healthcare systems, some countries’ healthcare or political systems allow for creative and integrated approaches to obesity prevention and treatment. This seminar will explore the global impact of obesity, and what lessons the United States and international communities can learn from each other.

Registration Deadline: September 8, 2022

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/obesity-research-task-force-symposium

Sep. 09, 2022 

Abstract Submission Due: NIDDK New Insights into Congenital Kidney Disease

Congenital diseases of the urinary tract can lead to a range of devastating conditions, including fetal loss or childhood or later-life kidney failure. The National Institute of Diabetes and Digestive and Kidney Diseases is planning a public workshop to discuss the challenges in moving beyond the current research state to an understanding of the mechanisms associated with congenital renal anomalies and low nephron endowment. 

The goal of the workshop is to broaden the current research field and promote multidisciplinary approaches among individuals with expertise in genetics, epigenetics, developmental biology, multi-omics, clinical phenotyping, the intrauterine environment, environmental exposures, and health disparities.

Abstract Submission Deadline: September 9, 2022

Registration Deadline: September 20, 2022

Meeting Dates: September 28-29, 2022

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/new-insights-congenital-kidney-disease

Sep. 13, 2022 

LIPID MAPS Webinar: "Not just fat" – Exploring Octadecanoids as Novel Bioactive Lipids in Inflammation"

LIPIDMAPS is hosting the webinar ""Not just fat" – Exploring Octadecanoids as Novel Bioactive Lipids in Inflammation"

Presented by: Assoc. Professor Craig Wheelock

Craig E. Wheelock is Head of the Unit of Integrative Metabolomics in the Institute of Environmental Medicine at the Karolinska Institute, Sweden, where he serves as director of the Integrative Molecular Phenotyping Laboratory (www.metabolomics.se). He is also a Distinguished Visiting Professor of Metabolomics at Gunma University, Japan.

Webinar Date: September 13th, 2022, 9am PDT

More Information: https://www.lipidmaps.org/resources/webinars/27

Sep. 15, 2022 

Entry Deadline: HuBMAP + HPA - Hacking the Human Body

In this coding competition, you’ll identify and segment functional tissue units (FTUs) across five human organs. You'll build your model using a dataset of tissue section images, with the best submissions segmenting FTUs as accurately as possible. If successful, you'll help accelerate the world’s understanding of the relationships between cell and tissue organization. With a better idea of the relationship of cells, researchers will have more insight into the function of cells that impact human health. Further, the Human Reference Atlas constructed by HuBMAP will be freely available for use by researchers and pharmaceutical companies alike, potentially improving and prolonging human life.

More Information: https://www.kaggle.com/competitions/hubmap-organ-segmentation/overview/description

Sep. 15, 2022 

NIH Webinar: Introduction to Generalist Repositories for NIH Data Sharing

Learn what a generalist repository is including key repository features and data sharing use cases for generalist repositories. Find out how generalist repositories fit into the NIH data sharing landscape and the new NIH Data Management and Sharing Policy.

Speakers: Sonia Barbosa (Dataverse), Jennifer Gibson (Dryad), Ana Van Gulick (Figshare), Nici Pfeiffer (Open Science Framework)

Moderated by: Ana Van Gulick (Figshare)

Webinar Date: Sep 15, 2022 12:00 PM PT

Other NIH Generalist Repository Ecosystem Initiative (GREI) Webinar Dates: October 12, November 10, & December 8

More Information: https://datascience.nih.gov/grei-collaborative-webinar-series

Sep. 16, 2022 

Registration Due: 2022 Annual Mid Atlantic Diabetes Obesity Research Symposium

The goal of this meeting is to encourage scientific exchanges, interactions, and collaborations at the regional level.

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/Annual-Mid-Atlantic-Diabetes-Obesity-Research-Symposium

Sep. 19-20, 2022 

NIH Workshop: Yet to Be Charted: Lymphatic System in Health and Disease

NIH is hosting a research workshop in September to help us better understand how the lymphatic system develops and functions in sickness and in health. The workshop aims to improve how we manage and treat lymphatic disorders. Hosted by the NHLBI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in coordination with the Trans-NIH Lymphatic Coordinating Committee, the workshop will bring together basic, clinical, and translational scientists, along with members of the lymphatics community, to explore the latest advances in the field and share research progress.

International experts will discuss current research, explore knowledge gaps, and identify opportunities in lymphatic disease research. People with lymphedema, lipedema, and other lymphatic diseases will share their personal experiences. Workshop organizers hope the event will build collaborative partnerships among scientists, clinicians, patients, and patient advocates. Featured topics include lymphedema and the role of lymphatics in obesity.

This virtual event is free and open to the public.

Meeting Dates: September 19-20, 2022 

Day 1: 8:20 a.m. - 2:40 p.m

Day 2: 8:25 a.m. - 3:20 p.m

More Information: https://www.nhlbi.nih.gov/events/2022/yet-be-charted-lymphatic-system-health-and-disease

Sep. 20, 2022 

Registration Due: NIDDK New Insights into Congenital Kidney Disease

Congenital diseases of the urinary tract can lead to a range of devastating conditions, including fetal loss or childhood or later-life kidney failure. The National Institute of Diabetes and Digestive and Kidney Diseases is planning a public workshop to discuss the challenges in moving beyond the current research state to an understanding of the mechanisms associated with congenital renal anomalies and low nephron endowment. 

The goal of the workshop is to broaden the current research field and promote multidisciplinary approaches among individuals with expertise in genetics, epigenetics, developmental biology, multi-omics, clinical phenotyping, the intrauterine environment, environmental exposures, and health disparities.

Meeting Dates: September 28-29, 2022

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/new-insights-congenital-kidney-disease

Sep. 21, 2022 

NIH Webinar: Long COVID Computational Challenge (L3C)

The RADx-Radical (RADx-rad) program at the NIH is launching the Long COVID Computational Challenge (L3C). NIH designed this challenge to support creative data-driven solutions that meaningfully advance the current understanding of the risks of developing PASC/Long COVID. The total prize for this Challenge will be up to $500,000. The primary objective of the Long COVID Computational Challenge (L3C) is to focus on the prognostic problem by developing AI/ML models and algorithms that serve as open-source tools for using structured medical records to identify which patients infected with SARS-CoV-2 have a high likelihood of developing PASC/Long COVID. Challenge participants are expected to develop, train, and test their models to aid in predicting the susceptibility to and likelihood of developing PASC/Long COVID in patients with SARS-CoV-2 infection.

Webinar Date: Sep 21, 2022 at 12:00PM PT

Challenge Submission Period: August 15- December 15, 2022

More Information: https://www.imagwiki.nibib.nih.gov/index.php/news-events/announcements/announcing-nih-long-covid-computational-challenge-l3c

Sep. 22, 2022 

NIH Data Management and Sharing (DMS) Policy 2-Part Webinar Series: Diving Deeper into the New NIH Data Management and Sharing Policy

Register now for this 2-part series A Conversation with NIH: Implementing the New Data Management and Sharing Policy. In this series, our policy experts will break down what the policy means for you and discuss key factors to consider when sharing data.

In this second webinar of the series, we will expand upon the information presented in the first webinar and dive deeper into topics including privacy protections for data from human participants and justifiable limitations on sharing data.

Webinar Date: September 22, 2022 at 10:30 AM – 12:00 PM PST

More Information: https://nexus.od.nih.gov/all/2022/07/19/register-today-for-the-nih-data-management-and-sharing-dms-policy-2-part-webinar-series/

Sep. 23, 2022 

2022 Annual Mid Atlantic Diabetes Obesity Research Symposium

The goal of this meeting is to encourage scientific exchanges, interactions, and collaborations at the regional level.

Location:  Bethesda, MD, USA

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/Annual-Mid-Atlantic-Diabetes-Obesity-Research-Symposium

Sep. 26-28, 2022

Helmholtz Diabetes Conference 2022

For the 9th time, the Helmholtz Zentrum München is organizing this high-impact conference series. Internationally leading scientists in diabetes research are joining us virtually to present and discuss their most recent data and achievements. Our overriding goal is to find new ways for the prevention and treatment of type 1 and type 2 diabetes. This conference will focus on the latest therepies in diabetes. The world’s leading faculty in this area will thus enrich this year’s program. Following our long-standing tradition, we will feature again the HelDi (Helmholtz Young Investigator in Diabetes) competition with selected talks by rising stars in the field of diabetes, and the presentation of the Helmholtz Diabetes Lecture. This year, Rudolf Zechner (University of Graz) will receive this award in recognition of his life-time achievements.

Location:  Munich, Germany

More Information: https://www.hd-conference.com/

Sep. 28-29, 2022 

NIDDK Workshop: New Insights into Congenital Kidney Disease

Congenital diseases of the urinary tract can lead to a range of devastating conditions, including fetal loss or childhood or later-life kidney failure. The National Institute of Diabetes and Digestive and Kidney Diseases is planning a public workshop to discuss the challenges in moving beyond the current research state to an understanding of the mechanisms associated with congenital renal anomalies and low nephron endowment. 

The goal of the workshop is to broaden the current research field and promote multidisciplinary approaches among individuals with expertise in genetics, epigenetics, developmental biology, multi-omics, clinical phenotyping, the intrauterine environment, environmental exposures, and health disparities.

Location:  Bethesda, MD, USA

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/new-insights-congenital-kidney-disease

Funding Opportunities Information and Deadlines in September 2022

Sep. 01, 2022 

NIDDK Funding Opportunity Application Due: NIDDK AMP-CMD Opportunity Pool Handbook

The AMP-CMD award “The next iteration of the AMP-T2D Knowledge Portal” (UM1DK105554), for the project period 5/1/2015 - 6/30/2025, includes an Opportunity Pool (OP). The OP provides $500,000 per year total cost, with a total allocation of $2,500,000 over the project period, to fund projects aligned with AMP-CMD goals that address gaps in the currently funded research. The AMP-CMD Data Coordinating Center (DCC) at the Broad Institute serves as the administrative hub of the OP. In this round under the UM1 award (Summer 2022), applications for year 3 are being considered. See Figure 1 for an overview of the OP application and award timeline.

More Information: https://kp4cd.org/OP_handbook_2022

Sep. 02, 2022 

NIH Funding Opportunity Letter of Intent Due: Regenerative Medicine Innovation Projects (RMIP) Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA) support the Regenerative Medicine Innovation Project (RMIP), which aims to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial’s rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. Applicants may use the RMIP Clinical Trial Planning Grant to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that explore and enable the evaluation of the safety and/or efficacy of RM interventions using adult stem cells that are not of embryonic or fetal origin.

Application Deadline: October 6, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-020.html

Sep. 02, 2022 

NIH Funding Opportunity Letter of Intent Due: Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 – Clinical Trial Not Allowed)

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act.

Applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness.

Application Deadline: October 6, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-019.html

Sep. 02, 2022 

NIH Funding Opportunity Letter of Intent Due: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required)

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act.

Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials.

This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications will be required to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results.

Application Deadline: October 6, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-017.html

Sep. 02, 2022 

NIDDK Pre-Application Webinar: Interventions that Address Structural Racism to Reduce Kidney Health Disparities FOAs

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will host a pre-application webinar for those interested in learning more about Funding Opportunity Announcements (FOAs):

• RFA-DK-22-014 NIH external link: Interventions that Address Structural Racism to reduce Kidney Health Disparities – (U01- Clinical Trial Required)

• RFA-DK-22-015 NIH external link: Interventions that Address Structural Racism to Reduce Kidney Health Disparities – Research Coordinating Center (U24 - Clinical Trial Not Allowed)

NIH staff members will provide a brief overview of the two FOAs and explain the goals and objectives of each. The webinar is open to all prospective applicants, though participation in the webinar is not required for submitting an application.

Webinar Date: September 2, 2022 at 10:00AM - 12:00PM EST (7:00AM - 9:00AM PST)

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/pre-application-webinar-for-interventions-that-address-structural-racism

Sep. 05, 2022 

NIH Funding Opportunity Application Due: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

More Information: https://grants.nih.gov/grants/guide/pa-files/pa-22-178.html

Sep. 05, 2022

NIH Funding Opportunity Application Due: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH and CDC awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH and CDC Institutes and Centers (ICs) based on their scientific missions.

More Information: https://grants.nih.gov/grants/guide/pa-files/pa-22-177.html

Sep. 05, 2022 

NIH Funding Opportunity Application Due: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

More Information: https://grants.nih.gov/grants/guide/pa-files/pa-22-176.html

Sep. 07, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.

Application Due Date: October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-011.html 

Sep. 07, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

Application Deadline: October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-012.html

Sep. 07, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D) to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.

Application Deadlines: October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-021.html

Sep. 20, 2022 

NIH Funding Opportunity Letter of Intent Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)

The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).

Letter of Intent Deadline: September 20, 2022

Application Deadline: October 20, 2022

More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html

Sep. 26, 2022

NIDDK Funding Opportunity Letter of Intent Due: Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed)

This U2C Funding Opportunity Announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 2 diabetes research (SEIC-T2D). A primary goal of the SEIC-T2D is to accelerate equitable engagement of individuals from and communities of diverse backgrounds and sectors in developing the research priorities and activities that involve them, particularly underserved communities, and those with the highest proportion of diabetes-related morbidity and mortality. The SEIC-T2D will provide highly specialized research resources to support field investigators by fully embedding communities, patients, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T2D will also establish a network consisting of multidisciplinary research investigators, including from underrepresented groups, with expertise in T2D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T2D prevention and treatment.

Application Deadline: October 26, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-001.html

Sep. 26, 2022 

NIDDK Funding Opportunity Letter of Intent Due:Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

Application Deadline: October 26, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-009.html

Sep. 26, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

Application Deadline: October 26, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-009.html

Sep. 26, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available.

Application Deadline: October 26, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-031.html

Sep. 27, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Promoting Organ and Tissue Donation Among Health Disparity Populations (R01 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the area of organ and tissue donation among health disparity populations, such as racial and ethnic minorities, the socioeconomically disadvantaged, underserved rural populations, sexual and gender minorities, and other underserved communities. Proposed studies may include studying individual-level factors such as attitudes, beliefs, and behaviors towards organ and tissue donation, as well as the need for transplantation. In addition, studies may include examining the influence of social determinants of health on disparities in organ and tissue donation. Support will be provided for testing various hypotheses related to the barriers and challenges of organ and tissue donation, as well as for facilitating the development of novel interventions. Successful approaches should ultimately lead to an increase in the number of health disparity populations participating in living and deceased organ and/or tissue donation.

Application Deadline: Oct. 27, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-003.html

Sep. 27, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist individuals with doctorate degrees (either clinical or professional) with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (https://www.niddk.nih.gov/research-funding/research-programs#urologic-diseases). This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Application Deadline: October 27, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-006.html

Sep. 30, 2022

NIH Funding Opportunity Response Due: Request for Information: Soliciting ideas for new NIH Common Fund programs

The purpose of this Request for Information (RFI) is to solicit ideas for potential NIH Common Fund programs.

More information:

https://grants.nih.gov/grants/guide/notice-files/NOT-RM-22-016.html

Sep. 30, 2022

NIH Funding Opportunity Application Due: Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional)

The ORWH and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women.

Application Deadline(s): September 30, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-od-22-014.html

Sep. 30, 2022 

NIH Career Program Application Due: Diabetes-Docs: Physician-Scientist Career Development Program

The DiabDocs program is now soliciting letters of intent for applications for a mentored career development program from a diverse group of early career physician scientists engaged in research relevant to type 1 diabetes (T1D) including basic, translational, clinical, epidemiology/biostatistics, informatics, health services or health policy projects. This national program (run by Dr. Maahs at Stanford and Dr. DiMeglio at IU) replaces the previous institutional K12 programs. Awards will provide promising investigators the opportunity to be mentored in research-intensive settings at their home institutions to compete successfully for an NIH K08/23 or similar Career Development Awards. 

Application Deadline: September 30, 2022

More Information: https://diabetescenters.org/sites/default/files/dco/National-K12-AD06_07_22.pdf